CEO: Francesco Maria Lavino

Advent Contact: Kaasim Mahmood

First in class anti-fungal agents

F2G has identified a novel fungal target essential for DNA synthesis, and so fungal growth and survival. The company has identified novel inhibitors of this enzyme with the lead candidate F901318 in Phase II clinical trials. F901318 has the potential to be the first new class of anti-fungal agent for over 30 years.

F2G Receives US FDA Breakthrough Therapy Designation for Olorofim

F2G Closes US$60.8 Million Financing to fund late stage development of novel mechanism antifungal agent

Francesco Maria Lavino appointed Chief Executive Officer of F2G Ltd